We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

64 hedge funds and large institutions have $192M invested in Oric Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

447% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $190K

96% more capital invested

Capital invested by funds: $98M → $192M (+$94.2M)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0.69% less ownership

Funds ownership: 82.63% → 81.94% (-0.69%)

16% less funds holding

Funds holding: 76 → 64 (-12)

67% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 18

Holders
64
Holders Change
-12
Holders Change %
-15.79%
% of All Funds
1.03%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
6
Increased
21
Reduced
20
Closed
18
Calls
$1.04M
Puts
$190K
Net Calls
+$850K
Net Calls Change
+$431K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$1.2M
2
Alkeon Capital Management
Alkeon Capital Management
New York
+$987K
3
PM
Prosight Management
Texas
+$823K
4
MAM
Monaco Asset Management
Monaco
+$730K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$673K

Top Sellers

1
O
OrbiMed
New York
-$1.62M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.12M
3
UOC
UBS O'Connor
Illinois
-$1.1M
4
BlackRock
BlackRock
New York
-$812K
5
DCM
DAFNA Capital Management
California
-$504K
Name Holding Trade Value Shares
Change 		Change in
Stake
State of Wisconsin Investment Board
26
State of Wisconsin Investment Board
Wisconsin
$865K -$39.5K -11,700 -7%
NM
27
Newtyn Management
New York
$854K +$67.5K +20,000 +16%
Acadian Asset Management
28
Acadian Asset Management
Massachusetts
$752K – – –
AI
29
Atom Investors
Texas
$729K -$22.7K -6,720 -5%
State Street
30
State Street
Massachusetts
$648K – – –
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$636K +$364K +107,688 New
BCM
32
Bridgeway Capital Management
Texas
$620K +$137K +40,500 +63%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$585K +$268K +79,310 +397%
Citadel Advisors
34
Citadel Advisors
Florida
$463K +$223K +66,196 +532%
Northern Trust
35
Northern Trust
Illinois
$430K -$1.04K -307 -0.4%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$350K – – –
Morgan Stanley
37
Morgan Stanley
New York
$339K +$67.1K +19,885 +53%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$328K -$380K -112,586 -67%
HSBC Holdings
39
HSBC Holdings
United Kingdom
$296K -$16.9K -5,000 -8%
Two Sigma Investments
40
Two Sigma Investments
New York
$274K -$430K -127,496 -73%
CIC
41
Cornercap Investment Counsel
Georgia
$274K -$76.3K -22,606 -33%
E
42
Ergoteles
New York
$250K -$139K -41,312 -49%
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$245K -$31K -9,174 -18%
Qube Research & Technologies (QRT)
44
Qube Research & Technologies (QRT)
United Kingdom
$234K +$47.4K +14,028 +55%
6CM
45
683 Capital Management
New York
$199K +$114K +33,800 New
Bank of America
46
Bank of America
North Carolina
$193K +$11K +3,262 +11%
Deutsche Bank
47
Deutsche Bank
Germany
$148K – – –
JRP
48
Jasper Ridge Partners
California
$123K – – –
Point72 Asset Management
49
Point72 Asset Management
Connecticut
$112K +$30.7K +9,100 +91%
Charles Schwab
50
Charles Schwab
California
$98.1K – – –
1
2
3 4

ORIC Hedge Fund Activity: Q4 2022 in Review

64 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2022, worth a combined $192M — up 96% from $98M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ORIC and 6 opened new positions — a net loss of 12 holders — while 20 trimmed existing stakes and 21 added.

The largest buyer was Millennium Management, adding an estimated $1.2M. The largest seller was OrbiMed, cutting an estimated $1.62M.

  • 64 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2022, down from 76 in Q3 2022.
  • Funds reported $192M of Oric Pharmaceuticals stock for Q4 2022, up 96% quarter-over-quarter.
  • 6 funds opened new Oric Pharmaceuticals positions in Q4 2022 and 18 closed out, a net change of -12 holders.
  • The largest Oric Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $1.2M added.
  • The largest Oric Pharmaceuticals seller in Q4 2022 was OrbiMed, an estimated $1.62M sold.

Based on aggregated 13F filings for Q4 2022.